Chemotherapy for brain metastases of lung cancer: A review

Annals of Oncology

Volumn 10, Issue 7, 1999, Pages 753-759

  Postmus, P E ^a   Smit, E F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Brain metastases; Chemotherapy; Lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOTEMUSTINE; HYDROXYUREA; IFOSFAMIDE; LOMUSTINE; MITOLACTOL; MITOMYCIN; PROCARBAZINE; TENIPOSIDE; TIOGUANINE; VINCRISTINE;

BLOOD BRAIN BARRIER; BRAIN METASTASIS; BRAIN RADIATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; HUMANS; LUNG NEOPLASMS;

EID: 0032802181     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008318515795     Document Type: Review

References (84)

1. Nugent JL, Bunn PA, Matthews MJ et al. CNS metastases in small cell bronchogenic carcinoma: Increasing frequency and changing pattern with lengthening survival. Cancer 1979; 44: 1885-93.
2. Rosen ST, Makuch RW, Lichter AS et al. Role of prophylactic cranial irradiation in prevention of central nervous system metastases in small-cell lung cancer: Potential benefit restricted to patients with complete response. Am J Med 1983; 74: 615-24.
3. Sorensen JB, Hansen HH, Hansen M et al. Brain metastases in adenocarcinoma of the lung: Frequency, risk groups and prognosis. J Clin Oncol 1988; 6: 1474-80.
4. Law A, Daly B, Madsen M et al. High incidence of isolated brain metastases (CNSMets) following complete response (CR) in advanced non-small-cell lung cancer (NSCLC): A new challenge. Proc Am Soc Clin Oncol 1997; 16: 447a (Abstr).
5. Komaki R, Cox JD, Stark R. Frequency of brain metastasis in adenocarcinoma and large-cell carcinoma of the lung: Correlation with survival, Int J Radiation Oncol Biol Phys 1983; 9: 1467-70.
6. Weissman D. Glucocorticoid treatment for brain metastases and epidural spinal cord compression: A review. J Clin Oncol 1988; 6: 543-51.
7. Noordijk EM, Vecht CH, Haaxma-Reiche H et al. The choice of treatment of single brain metastases should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 1994; 29: 7117.
8. Vecht CJ, Haaxma-Reiche H, Noordijk EM et al. Treatment of single brain metastases: Radiotherapy alone or combined with neurosurgery? Ann Neurol 1993; 33: 483-90.
9. Phillips MH, Stelzer KJ, Griffin TW et al. Stereotactic radio-surgery: A review and comparison of methods. J Clin Oncol 1994; 12: 1085-99.
10. Hagedorn HE, Haaxma-Reiche H, Canrinus AA et al. Results of whole brain radiotherapy for brain metastases of small-cell lung cancer. Lung Cancer 1993; 8: 293-300.
11. Bach F, Sorensen JB, Adrian L et al. Brain relapses in chemotherapy-treated small-cell lung cancer: A retrospective review of two time-dose regimens of therapeutic brain irradiation. Lung Cancer 1996; 15: 171-81.
12. Postmus PE, Haaxma-Reiche H, Gregor A et al. Brain-only metastases of small-cell lung cancer: Efficacy of whole brain radiotherapy. An EORTC phase II study. Radiother Oncol 1998; 46: 29-32.
13. Donelli MG, Zucchetti M, D'Incalci M. Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol 1992; 30: 251-60.
14. Thiebaut F, Tsuoro T, Hamada H et al. Cellular localization of the multidrug resistance gene product in normal human tissues. Proc Natl Acad Science USA 1987; 84: 7735-8.
15. Schinkel AH, Wagenaar E, van Deemter L et al. Absence of the mdrla P-Glycoprotein in Mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxine, and cyclosporin A. J Clin Invest 1995; 96: 1698-705.
16. Schinkel AH, Wagenaar E, Mol CA et al. P-Glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97: 2517-24.
17. Rodriguez E, Delucchi A, Cano F. Neurotoxicity caused by cyclosporin A in renal transplantation in children. Rev Med Chil 1992; 120: 300-3.
18. Weber DM, Dimipoulos MA, Alexamian R. Increased neurotoxicity wit VAD-cyclosporin in multiple myeloma. Lancet 1993; 341: 558-9.
19. Arico M, Nespoli L, Pora Fet al. Severe acute encephalopathy following inadvertent intrathecal doxorubicin administration. Med Pediatr Oncol 1990; 18: 261-3.
20. Barbui T, Rambaldi A, Parenzan Let al. Neurological symptoms and coma associated with doxorubicin administration during cyclosporin therapy. Lancet 1992; 339: 1421.
21. Beck WT, Kuttesch JF. Neurological symptoms associated with cyclosporin plus doxorubicin. Lancet 1992; 340: 496.
22. Stewart DJ, Lu K, Benjamin RS et al. Concentrations of vinblastine in human intracerebral tumor and other tissues. J Neurooncol 1983; 1: 139-44.
23. Stewart DJ, Leavens M, Maor M et al. Human central nervous system distribution of cis-diamminedichloroplatinum and use as radiosensitizer in malignant brain tumors. Cancer Res 1982; 42: 2474-9.
24. Kiya K, Uozumi T, Ogasawara H et al. Penetration of etoposide into human malignant brain tumors after intravenous and oral administration. Cancer Chemother Pharmacol 1992; 29: 339-42.
25. Rosenblum MG, Stewart DJ, Yap BS et al. Penetration of methyl-glyoxal bis(guanylhydrazone) into cerebral tumors in humans. Cancer Res 1981; 41: 459-62.
26. Stewart DJ, Leavans M, Friedman J et al. Penetration of N-(phosphonacetyl)-L-asparate into human central nervous system and intracerebral tumor. Cancer Res 1980; 40: 3163-6.
27. Stewart DJ, Benvenuto JA, Levans M et al. Human central nervous system pharmacology of pentamethylmelamine and its metabolites. J Neurooncol 1983; 1: 357-64.
28. Postmus PE, Holthuis JJM, Haaxma-Reiche H et al. Penetration of VP 16-213 into cerebrospinal fluid after high-dose administration. J Clin Oncol 1984; 2: 215-20.
29. Green RM, Stewart DJ, Hugenholtz H et al. Human central nervous system pharmacology of mitoxantrone. J Neurooncol 1988; 6: 75-83.
30. Stewart DJ, Richard M, Hugenholtz H et al. Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors. J Neurooncol 1984; 2: 133-9.
31. Lesser GJ. Chemotherapy of cerebral metastases from solid tumors. Neurosurgery Clin North Am 1996; 7: 527-36.
32. Boogerd W, Voss VW, Hart AAM et al. Brain metastases in breast cancer: Natural history, prognostic factors and outcome. J Neurooncol 1993; 15: 165-74.
33. Gerl A, Clemm C, Kohl P et al. Central nervous system as sanctuary site of relapse in patients treated with chemotherapy for metastatic testicular cancer. Clin Exp Metast 1994; 12: 226-30.
34. Aroney RS, Aisner J, Wesley MN et al. Value of prophylactic cranial irradiation given at complete remission in small-cell lung carcinoma. Cancer Treat Rep 1983; 67: 675-82.
35. Hirsch FR, Paulson OB, Hansen HH et al. Intracranial metastases in small-cell carcinoma of the lung. Correlation of Clinical and autopsy findings. Cancer 1982; 50: 2433-7.
36. Cohen MH, Creaven PJ, Fossieck BE et al. Intensive chemotherapy of small-cell bronchogenic carcinoma. Cancer Treat Rep 1977; 61: 349-54.
37. Cohen MH, Ihde DC, Bunn PA et al. Cyclic alternating combination chemotherapy for small-cell bronchogenic carcinoma. Cancer Treat Rep 1979; 63: 163-70.
38. Neystrom ES, Capizzi RL, Rudnick SA et al. High-dose methotrexate in small-cell lung cancer. Lack of efficacy in preventing CNS relapse. Cancer 1983; 51: 1056-61.
39. Biesma B, Smit EF, Postmus PE. Chemotherapy resistance in small cell lung cancer: Consequences for the clinician and future prospects. In Bernal SD (ed): Drug Resistance in Oncology. New York: Marcel Dekker 1997; 1-25.
40. Cracker EF, Zimmerman RA, Phelps ME et al. The effects of steroids on the extravascular distribution of radiographic contrast material and technetium pertechnate in brain tumors as determined by computed tomography. Radiology 1976; 119: 471-4.
41. Cairncross JG, Macdonald DR, Pexman JHW et al. Steroid-induced CT changes in patients with recurrent malignant glioma. Neurology 1988; 38: 724-6.
42. Watling CJ, Lee DH, Macdonald DR et al. Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol 1994; 12: 1886-9.
43. Postmus PE, Haaxma-Reiche H, Sleijfer DTh et al. High-dose etoposide for brain metastases of small-cell lung cancer. A phase II study. Br J Cancer 1989; 59: 254-6.
44. Kristjansen PG, Hansen HH. Brain metastases from small-cell lung cancer treated with combination chemotherapy. Eur J Cancer Clin Oncol 1988; 24: 545-9.
45. Lee JS, Murphy WK, Glisson BS et al. Primary chemotherapy of brain metastases in small-cell lung cancer. J Clin Oncol 1989; 7: 916-22.
46. Humblet Y, Weynants P, Bosly A et al. Carboplatin in association with etoposide and either adriamycin or epirubicin for untreated small-cell lung cancer: A dose escalation study of carboplatin. Med Oncol Tumor Pharmacother 1989; 6: 207-12.
47. Twelves CJ, Souhami RL, Harper PG et al. Cerebral metastases in small-cell lung cancer respond to systemic chemotherapy. Br J Cancer 1990; 61: 147-50.
48. Kristjansen PEG, Sorenson PS, Hansen MS et al. Prospective evaluation of the effect on initial brain metastases from small-cell lung cancer of platinum-etoposide based induction chemotherapy followed by an alternating drug regimen. Ann Oncol 1993; 4: 579-83.
49. Malacarne P, Santini A, Maestri A. Response of brain metastases from lung cancer to systemic chemotherapy with carboplatin and etoposide. Oncology 1996; 53: 210-3.
50. Tanaka H, Takifuji N, Masuda N et al. Systemic chemotherapy for brain metastases from small-cell lung cancer. Jap J Thorac Dis 1993; 31: 492-7.
51. Crino L, Palladino MA, Darwish S et al. Combination chemotherapy with cisplatin and teniposide(VM26) or etoposide (VP16) for brain metastasis of small-cell lung cancer (SCLC): A phase II study. Lung Cancer 1997; 18 (Suppl 1): 47 (Abstr).
52. Kaba SE, Kyritsis AP, Hess K et al. TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J Clin Oncol 1997; 15: 1063-70.
53. Kleisbauer JP, Vesco D, Orehek J et al. Treatment of brain metastases of lung cancer with high doses of etoposide (VP-16). Cooperative study from the group francais. Eur J Cancer Clin Oncol 1988; 24: 131-5.
54. Giaccone G, Donadio M, Bonardi GM et al. Teniposide (VM26): An effective treatment for brain metastases of small-cell carcinoma of the lung. Eur J Cancer Clin Oncol 1988; 24: 629-31.
55. Postmus PE, Smit EF, Haaxma-Reiche H et al. Teniposide for brain metastases of small-cell lung cancer: A phase II study. J Clin Oncol 1995; 13: 660-5.
56. Ardizzoni A, Hansen H, Dombernowsky P et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. J Clin Oncol 1997; 15: 2090-6.
57. Groen HJM, Smit EF, Haaxma-Reiche H et al. Carboplatin as second-line treatment for recurrent or progressive brain metastases from small-cell lung cancer. Eur J Cancer 1993; 12: 1696-9.
58. Kristensen CA, Kristjansen PE, Hansen HH. Systemic chemotherapy of brain metastases from small-cell lung cancer: A review. J Clin Oncol 1992; 10: 1498-502.
59. Hazel van GA, Scott M, Eagan RT. The effect of CNS metastases on the survival of patients with small-cell cancer of the lung. Cancer 1983; 51: 933-7.
60. Kochhar R, Frytak S, Shaw EG. Survival of patients with extensive small-cell lung cancer who have only brain metastases at initial diagnosis. Am J Clin Oncol 1997; 20: 125-7.
61. Postmus PE, Haaxma-Reiche H, Gregor A et al. The role of radiotherapy in the treatment of brain metastases of small-cell lung cancer. An EORTC phase II and phase III study. Proc Am Soc Clin Oncol 1996; 15: 381 (Abstr 1141).
62. Non-Small-Cell Lung Cancer Collaborative Group. Chemotherapy in non-small-cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899-909.
63. Billingham LJ, Cullen MH, Woods J et al. Mitomycin, ifosfamide and cisplatin (MIC) in non-small-cell lung cancer (NSCLC): Results of a randomised trial evaluating palliation & quality of life. Lung Cancer 1997; 18 (Suppl 1): 9 (Abstr).
64. Bunn PA, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small-cell lung cancer: A review of the literature and future directions. Clin Cancer Res 1998; 5: 1087-100.
65. Kleisbauer JP, Guerin JC, Arnaud A et al. Chemotherapy with high-dose cisplatin in brain metastasis of lung cancer. Bull Cancer 1990; 77: 661-5.
66. Riviere A, LeCesne A, Berille J et al. Cisplatin-fotemustine combiantion in inoperable non-small-cell lung cancer: Preliminary report of a French multicenter phase II trial. Eur J Cancer 1994; 30A: 587-90.
67. Cotto C, Berille J, Souquet PJ et al. A phase II trial of fotemustine and cisptatin in central nervous system metastases from non-small-cell lung cancer. Eur J Cancer 1996; 32A: 69-71.
68. Pujol J-L, Monnier A, Berille J et al. Phase II study of nitrosurea fotemustine as single-drug chemotherapy in poor prognosis non-small-cell lung cancer. Br J Cancer 1994; 69: 1136-40.
69. Cumin I, Lacroix H, Mahe H et al. Efficacy of the combination of mitomycin, ifosfamide and cisplatin with irradiation for the treatment of cerebral metastasis in non-small-cell lung carcinoma. Bull Cancer 1995; 82: 57-62.
70. Santini A, Malacarne P, Indelli M et al. Combination chemotherapy with carboplatin and etoposide of brain metastases from cancer. Eur J Cancer 1994; 30A: 1204-5.
71. Minotti V, Crino L, Meacci ML et al. Chemotherapy with cisplatin and teniposide for cerebral metastasses in non-small-cell lung cancer. Lung Cancer 1998; 20: 93-8.
72. Li JH, Kang SJ, Zheng H. Teniposide plus lomustini in the treatment of brain metastasis in lung cancer. Lung Cancer 1997; 18 (Suppl 1): 15 (Abstr).
73. Ando Y, Sugiura S, Ando M et al. Acceptability of patients with brain metastases for clinical trials of chemotherapy for metastatic non-small-cell lung cancer. Am J Clin Oncol 1996; 19: 478-82.
74. Lassen U, Andersen P, Daugaard G et al. Metabolic and hemodynamic evaluation of brain metastases from small-cell lung cancer with positron emission tomography. Clin Cancer Res 1998; 4: 2591-97.
75. Larcos G, Maisey MN. FDG-PET screening for cerebral metastases in patients with suspected malignancy. Nucl Med Comm 1996; 17: 197-8.
76. Arriagada R, Auperin A, Pignon JP et al. Prophylactic cranial irradiation overview (PCIO) in patients with small-cell lung cancer (SCLC) in complete remission (CR). Proc Am Soc Clin Oncol 1998; 17: 457a (Abstr).
77. Holm B, Sehested M, Jensen PB. ICRF-187 enables dose escalation of the topoisomerase II poisons, etoposide and teniposide. An in vivo model targeting high-dose chemotherapy to CNS tumors. Lung Cancer 1997; 18 (Suppl 1): 26 (Abstr).
78. Elliott PJ, Hayward NJ, Huff MR et al. Unlocking the blood-brain barrier: A role for RMP-7 in brain tumor therapy. Exp Neurol 1996; 141: 214-24.
79. Doctrow SR, Abelleira SM, Curry LA et al. The bradykinin analog RMP-7 increases intracellular free calcium levels in rat brain microvascular cells. J Pharmacol Experiment Therapeut 1994; 271: 229-37.
80. Bradshaw DM, Arceci RJ. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 1998; 16: 3674-90.
81. Figueredo AF, Arnold A, Goodyear M et al. Addition of verapamil and tamoxifen to the initial chemotherapy of small-cell lung cancer. A phase I-II study. Cancer 1990; 65: 1895-902.
82. Milroy R, Paul J, Cram L et al. Randomized trial of verapamil in addition to chemotherapy in small-cell lung cancer. Br J Cancer 1993; 68: 813-8.
83. Wheeler H, Bell D, Levi J. A randomised trial of doxorubicin, etoposide and vindesine with or without verapamil in small-cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1998; 7: 208 (Abstr).
84. Millward MJ, Cantwell BMJ, Munro NC et al. Oral verapamil with chemotherapy for advanced non-small-cell lung cancer: A randomised study. Br J Cancer 1993; 67: 1031-5.